🚚 Free shipping on all orders above $299 · 30 days money back guarantee · Helpline +1 251-332-4105

Ceritinib 150 mg

$380.00$38.00 per capsule · 10 capsules
(2 customer reviews)
Choose pack sizePrice per capsule shown

Want to order in bulk / B2B price?

Tracked, discreet delivery

Ships in plain packaging with a tracking number. Delivery time for this product: 6 to 15 days. Free shipping on orders above $299.

30 days money back guarantee

Damaged, missing or only part of your order arrived? Choose a new package or a full refund.

Questions before you order?

Call +1 251-332-4105 or email [email protected].

SECURE CHECKOUT
DISCOVER
MasterCard
VISA

Share

Product verification: Ceritinib 150 mg is commonly supplied as an oral capsule. Verify the manufacturer, dosage form, pack size, and country-specific regulatory status before publishing.

Important Safety Warning: Ceritinib is a prescription anticancer medicine that can cause severe gastrointestinal reactions, liver injury, interstitial lung disease, QT interval prolongation, high blood sugar, pancreatitis, and fetal harm. Treatment requires specialist oncology supervision and appropriate laboratory monitoring.

What Is Ceritinib 150 mg?

Ceritinib 150 mg is an oral targeted anticancer medicine belonging to the tyrosine kinase inhibitor class.

It is used to treat selected patients with anaplastic lymphoma kinase-positive (ALK-positive) metastatic non-small cell lung cancer.

ALK-positive lung cancer contains a genetic alteration that produces abnormal ALK signaling, encouraging cancer cell growth and survival.

Ceritinib works by inhibiting ALK tyrosine kinase activity and disrupting signaling pathways that promote tumor cell proliferation.

Unlike conventional cytotoxic chemotherapy, ceritinib is a molecularly targeted therapy.

The 150 mg strength refers to the amount of ceritinib contained in each capsule.

It does not mean that one capsule is the standard daily treatment dose.

For the reference Zykadia formulation, the recommended adult regimen is 450 mg once daily with food, equivalent to three 150 mg capsules, unless the oncologist prescribes a different regimen.

Ceritinib has demonstrated clinical activity in ALK-positive NSCLC, including selected patients previously treated with other ALK inhibitors.

However, newer ALK-targeted medicines are often preferred in current treatment pathways because of differences in efficacy, central nervous system activity, and tolerability.

Common Reasons for Prescribing Ceritinib 150 mg

  • ALK-positive metastatic non-small cell lung cancer
  • Molecularly confirmed ALK-rearranged NSCLC
  • Targeted therapy for selected lung cancer patients
  • Selected patients previously treated with other ALK inhibitors
  • Oncology-directed management of metastatic NSCLC
  • Tumor growth control in susceptible cancers
  • Individualized targeted anticancer treatment

Important: Ceritinib is not appropriate for all lung cancers. ALK testing is essential before treatment for its established NSCLC indication.

How Does Ceritinib 150 mg Work?

1. Targets Anaplastic Lymphoma Kinase

Ceritinib inhibits ALK, a receptor tyrosine kinase that can become abnormally activated in certain cancers.

2. Blocks Abnormal ALK Signaling

ALK gene rearrangements can produce abnormal fusion proteins that promote cancer cell growth.

Ceritinib inhibits the kinase activity of susceptible ALK fusion proteins.

3. Inhibits Cancer Cell Proliferation

By blocking ALK signaling, ceritinib can interfere with pathways that support tumor cell multiplication.

4. Disrupts Cell Survival Pathways

ALK inhibition can affect downstream signaling pathways involved in cancer cell survival.

5. Promotes Cancer Cell Death

In susceptible ALK-positive cancer cells, inhibition of abnormal signaling may contribute to cell death.

6. Helps Reduce Tumor Growth

Ceritinib may reduce tumor size or slow disease progression in responsive patients.

7. Provides Molecularly Targeted Therapy

Treatment selection is based on identifying the relevant molecular abnormality.

8. Supports Disease Control

When effective and tolerated, ceritinib may help control metastatic ALK-positive NSCLC.

Important: Not all ALK resistance mutations respond equally to ceritinib. Molecular findings and previous treatment history influence the selection of ALK inhibitors.

Uses of Ceritinib 150 mg

1. ALK-Positive Non-Small Cell Lung Cancer

Ceritinib is used to treat selected patients with ALK-positive NSCLC.

2. Metastatic ALK-Positive NSCLC

The established indication for the reference medicine includes metastatic ALK-positive non-small cell lung cancer.

3. Molecularly Targeted Lung Cancer Treatment

Ceritinib may be selected when tumor testing confirms an ALK alteration and the oncology team considers it appropriate.

4. Previously Treated ALK-Positive NSCLC

Ceritinib has demonstrated activity in certain patients previously treated with other ALK-targeted therapies.

The effectiveness depends on the resistance mechanism and prior treatment history.

5. Tumor Growth Control

Ceritinib may help slow tumor growth in susceptible ALK-positive cancers.

6. Reduction of Tumor Burden

Some patients experience measurable tumor shrinkage during treatment.

7. Disease Progression Management

Ceritinib may delay disease progression in responsive patients.

8. Selected Patients With Brain Metastases

Ceritinib has demonstrated intracranial activity in some patients with ALK-positive NSCLC.

However, its suitability for brain metastases depends on the clinical setting, and other ALK inhibitors may be preferred.

9. Alternative Targeted Treatment

An oncologist may consider ceritinib when other treatment options are unsuitable or unavailable.

10. Long-Term Oncology Management

Treatment may continue while the medicine remains effective and adverse effects are manageable.

Important: Ceritinib is not a universal lung cancer medicine and should not be promoted as a cure for metastatic NSCLC.

Ceritinib 150 mg Dosage and Administration

Ceritinib must be prescribed and monitored by an oncology specialist.

General Dosage Information

Dosage InformationDetails
Capsule Strength150 mg
Active IngredientCeritinib
Administration RouteOral
Reference Adult Dose450 mg once daily with food
Number of 150 mg CapsulesThree capsules for the reference 450 mg regimen
Administration FrequencyOnce daily
Food InstructionsTake with food
Treatment DurationUntil disease progression or unacceptable toxicity, as directed
Dose AdjustmentsBased on adverse effects, organ function, and drug interactions
Medical SupervisionRequired throughout treatment

Important: The 450 mg once-daily regimen with food is based on reference Zykadia prescribing information. It is not an individualized prescription. The treating oncologist must determine the appropriate dose and any modifications.

General Administration Instructions

  1. Take ceritinib exactly as prescribed by the oncologist.
  2. Take the medicine at approximately the same time each day.
  3. Take ceritinib with food.
  4. Swallow the capsules whole with water.
  5. Do not crush, chew, or open the capsules.
  6. Do not independently increase or reduce the dose.
  7. Avoid grapefruit and grapefruit juice during treatment.
  8. Report persistent nausea, vomiting, or diarrhea.
  9. Report yellowing of the skin or eyes.
  10. Report new or worsening breathing difficulties.
  11. Attend scheduled laboratory and medical appointments.
  12. Inform the oncology team about all other medicines and supplements.

Should Ceritinib 150 mg Be Taken With Food?

Yes.

The reference ceritinib regimen is taken with food.

Food increases ceritinib exposure, and the approved 450 mg regimen with food was established to provide appropriate exposure while improving gastrointestinal tolerability compared with the older 750 mg fasting regimen.

What If a Dose Is Missed?

According to reference prescribing information, a missed dose may be taken if the next scheduled dose is more than 12 hours away.

If the next dose is within 12 hours, skip the missed dose.

Do not double the dose.

What If Vomiting Occurs After a Dose?

Do not take an additional dose to replace the vomited dose.

Take the next dose at the scheduled time unless the oncology team advises otherwise.

What If Too Much Ceritinib Is Taken?

Contact the oncology team or seek urgent medical attention.

An overdose may increase the risk of serious adverse effects.

Can Ceritinib Be Stopped Suddenly?

Do not independently stop or change treatment.

The oncology team may temporarily interrupt, reduce, or discontinue ceritinib because of adverse reactions, disease progression, or other clinical circumstances.

How Long Does Ceritinib 150 mg Take to Work?

Ceritinib begins inhibiting its molecular target after absorption.

However, measurable cancer treatment responses usually require several weeks.

The oncology team may evaluate treatment effectiveness through imaging studies, symptom assessments, and other clinical findings.

The time required depends on tumor characteristics, previous treatments, disease burden, and individual response.

Some patients may notice improvement in cancer-related symptoms before formal imaging confirms a response.

However, symptom improvement alone does not establish treatment effectiveness.

Common Side Effects

Possible side effects include:

  • Diarrhea
  • Nausea
  • Vomiting
  • Abdominal pain
  • Fatigue
  • Reduced appetite
  • Weight loss
  • Constipation
  • Elevated liver enzymes
  • Increased blood glucose
  • Elevated creatinine
  • Rash

Gastrointestinal adverse effects are particularly common with ceritinib.

Potentially Harmful Effects & Serious Health Risks

1. Severe Diarrhea

Ceritinib may cause significant diarrhea that can lead to dehydration and treatment interruption.

2. Severe Nausea and Vomiting

Persistent nausea and vomiting may interfere with food intake and hydration.

3. Dehydration

Fluid loss from gastrointestinal adverse effects may cause dehydration.

4. Liver Injury

Ceritinib can cause serious liver toxicity, including potentially life-threatening liver injury.

5. Interstitial Lung Disease

Ceritinib may cause interstitial lung disease or pneumonitis.

6. QT Interval Prolongation

Ceritinib can prolong the QT interval and may increase the risk of serious heart rhythm abnormalities.

7. Bradycardia

Ceritinib may cause a slow heart rate.

8. Hyperglycemia

Ceritinib may increase blood glucose levels, including in patients with diabetes.

9. Pancreatitis

Ceritinib can cause pancreatitis, which may be serious.

10. Elevated Pancreatic Enzymes

Increased amylase and lipase levels may occur during treatment.

11. Kidney Function Changes

Changes in creatinine and kidney-related laboratory results may occur.

12. Reduced Appetite and Weight Loss

Persistent gastrointestinal adverse effects may contribute to reduced nutritional intake and weight loss.

13. Embryo-Fetal Toxicity

Ceritinib may harm an unborn baby.

Certain medicines can increase ceritinib exposure and the risk of adverse effects.

15. Treatment Discontinuation Due to Toxicity

Severe adverse reactions may require dose interruption, reduction, or permanent discontinuation.

Emergency warning: Seek urgent medical assessment for new or worsening shortness of breath, severe persistent vomiting or diarrhea, fainting, palpitations, severe abdominal pain, jaundice, or symptoms of significant dehydration.

Contraindications & Safety Precautions

1. Hypersensitivity

Patients with a serious allergic reaction to ceritinib or formulation ingredients should not continue treatment without specialist assessment.

2. Liver Disease

Ceritinib can cause liver injury. Patients with liver disease require careful assessment and monitoring.

3. Severe Hepatic Impairment

Patients with severe liver impairment may require dose adjustment according to applicable prescribing information.

4. Gastrointestinal Disorders

Persistent diarrhea, nausea, vomiting, or abdominal pain should be reported promptly.

5. Dehydration Risk

Adequate hydration and early management of gastrointestinal adverse effects are important.

6. Interstitial Lung Disease

New cough, fever, or worsening breathlessness may indicate serious pulmonary toxicity.

7. Heart Rhythm Disorders

Patients with QT prolongation or other rhythm disorders may require additional assessment.

8. Bradycardia

Patients with a slow heart rate or those taking heart rate-lowering medicines require appropriate monitoring.

9. Diabetes

Ceritinib may increase blood glucose levels.

Patients with diabetes may require closer glucose monitoring.

10. Pancreatitis

Severe abdominal pain, especially when accompanied by vomiting, requires prompt medical assessment.

11. Kidney Disease

Kidney function should be monitored when clinically indicated.

12. Pregnancy

Ceritinib can cause fetal harm.

Patients who are pregnant or planning pregnancy should discuss treatment risks with their oncology specialist.

13. Contraception

Patients who can become pregnant should use effective contraception during treatment and for the period specified by the approved product labeling after the final dose.

Patients with partners who can become pregnant should also follow the applicable contraception recommendations.

14. Breastfeeding

Breastfeeding is not recommended during ceritinib treatment and for the period specified by the applicable product labeling after treatment.

15. Children

The safety and effectiveness of ceritinib have not been established for routine pediatric use.

16. Older Adults

Older patients may require additional monitoring because of adverse effects and other medical conditions.

17. Drug Interactions

Potentially important interactions include:

  • Strong CYP3A Inhibitors: May increase ceritinib exposure.
  • Strong CYP3A Inducers: May reduce ceritinib exposure.
  • Ketoconazole: May increase ceritinib concentrations.
  • Rifampicin: May reduce ceritinib concentrations.
  • Certain Antifungals: May alter ceritinib exposure.
  • Certain Antibiotics: May affect ceritinib metabolism.
  • QT-Prolonging Medicines: May increase the risk of heart rhythm abnormalities.
  • Heart Rate-Lowering Medicines: May increase bradycardia risk.
  • Certain CYP3A or CYP2C9 Substrates: Ceritinib may increase their exposure.
  • Herbal Supplements: Some may affect ceritinib metabolism.

18. Grapefruit Interaction

Avoid grapefruit and grapefruit juice because they may increase ceritinib exposure.

19. Food Instructions

Ceritinib should be taken with food according to the reference prescribing information.

20. Medical Monitoring

Healthcare professionals may monitor:

  • Liver function
  • Blood glucose
  • Electrolytes
  • Kidney function
  • Heart rate
  • Electrocardiogram (ECG) when indicated
  • Amylase and lipase
  • Gastrointestinal adverse effects
  • Hydration status
  • Pulmonary symptoms
  • Body weight
  • Treatment response
  • Imaging findings
  • Need for dose adjustment or interruption

Advantages

  • Oral targeted anticancer therapy.
  • Selective inhibition of ALK signaling.
  • Activity against selected ALK-positive NSCLC.
  • Used in metastatic lung cancer treatment.
  • May help delay disease progression in responsive patients.
  • May reduce tumor burden.
  • Has demonstrated activity in selected previously treated patients.
  • Has demonstrated intracranial activity in some patients.
  • Does not require intravenous administration.
  • Once-daily administration.
  • Established clinical evidence for selected indications.
  • May be continued while clinically effective and tolerable.

Disadvantages / Limitations

  • Not effective against every lung cancer.
  • Requires ALK molecular testing.
  • May cause severe diarrhea.
  • May cause nausea.
  • May cause vomiting.
  • May cause abdominal pain.
  • May cause dehydration.
  • May cause liver injury.
  • May cause interstitial lung disease.
  • May cause QT interval prolongation.
  • May cause bradycardia.
  • May cause hyperglycemia.
  • May cause pancreatitis.
  • May cause elevated pancreatic enzymes.
  • May cause reduced appetite.
  • May cause weight loss.
  • Can harm an unborn baby.
  • Requires oncology monitoring.
  • May interact with certain medicines.
  • Grapefruit must be avoided.
  • Resistance to treatment can develop.
  • Newer ALK inhibitors may be preferred in many treatment settings.

Important Notes

Generic Name: Ceritinib.

Strength: 150 mg.

Drug Class: Tyrosine Kinase Inhibitor.

Therapeutic Category: Targeted Anticancer Medicine.

Primary Use: ALK-positive metastatic NSCLC.

Molecular Target: Anaplastic Lymphoma Kinase.

Mechanism: Inhibition of ALK tyrosine kinase signaling.

Administration Route: Oral.

Reference Adult Dose: 450 mg once daily with food.

Capsule Strength: 150 mg per capsule.

Food Instructions: Take with food.

Major Warning: Gastrointestinal toxicity, liver injury, interstitial lung disease, QT prolongation, bradycardia, hyperglycemia, pancreatitis, and fetal harm.

Pregnancy Warning: Can cause fetal harm.

Breastfeeding Warning: Not recommended during treatment.

Monitoring: Liver function, blood glucose, electrolytes, cardiac status, pancreatic enzymes, and treatment response.

Prescription Status: Prescription-Only Anticancer Medicine.

Storage: Follow manufacturer instructions.

Frequently Asked Questions

1. What is Ceritinib 150 mg used for?

Ceritinib 150 mg is a targeted anticancer medicine used in selected treatment regimens for ALK-positive metastatic non-small cell lung cancer.

2. Is Ceritinib a chemotherapy medicine?

Ceritinib is a targeted anticancer medicine, not conventional cytotoxic chemotherapy.

3. How does Ceritinib work?

It inhibits ALK tyrosine kinase signaling, interfering with cancer cell growth and survival in susceptible ALK-positive tumors.

4. Can Ceritinib treat lung cancer?

Yes. It is used for selected patients with ALK-positive metastatic NSCLC.

5. Does Ceritinib work for every lung cancer?

No. Its established use depends on the presence of an ALK alteration and other clinical factors.

6. Is Ceritinib 150 mg the standard daily dose?

No. The reference adult regimen is 450 mg once daily with food, equivalent to three 150 mg capsules. The oncologist determines the prescribed dose.

7. How should Ceritinib 150 mg be taken?

Take the prescribed number of capsules orally with food, according to the oncologist’s instructions.

8. Can Ceritinib be taken without food?

The current reference regimen is taken with food. Patients should follow the prescribed product instructions.

Product DetailsInformation
Product NameCeritinib 150 mg
Generic NameCeritinib
Active IngredientCeritinib
Strength150 mg
Dosage FormOral Capsule
Drug ClassTyrosine Kinase Inhibitor (TKI)
Therapeutic CategoryTargeted Anticancer Medicine
Primary UseALK-positive metastatic non-small cell lung cancer (NSCLC)
Molecular TargetAnaplastic Lymphoma Kinase (ALK)
Mechanism of ActionInhibition of ALK tyrosine kinase signaling
Administration RouteOral
Reference BrandZykadia
ManufacturerVaries by brand; verify product packaging
Pack SizeVerify from product packaging
Prescription StatusPrescription-Only Anticancer Medicine
StorageFollow manufacturer instructions; generally store at controlled room temperature
Pack sizes10 capsules, 20 capsules, 30 capsules

2 reviews for Ceritinib 150 mg

  1. Alan (verified owner) –

    Viral Care is my shield against seasonal sickness.

  2. Max (verified owner) –

    Viral Care is my shield against seasonal sickness.

Add a review

Your email address will not be published. Required fields are marked *

Bulk / B2B price inquiry

Tell us what you need and we’ll reply by email.